BlackRock, Inc. 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-29 3:26 pm Purchase | 2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | BlackRock Inc. BLK | 3,566,611 6.400% | 231,710 (+6.95%) | Filing |
| 2023-02-01 4:54 pm Sale | 2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | BlackRock Inc. BLK | 3,334,901 6.100% | -62,639 (-1.84%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | BlackRock Inc. BLK | 3,397,540 6.600% | 3,397,540 (New Position) | Filing |